Cenobamate, marketed as XCOPRI in the US and ONTOZRY in the EU, provides various dosage choices to improve treatment adherence and efficacy.
SK Life Science’s cenobamate via its multimodal approach, provides much-needed relief for patients with partial-onset seizures by reducing repetitive neuronal firing and hyperexcitability.
Despite a copious amount of antiepileptics in the current market, a significant percentage of individuals still experience uncontrolled seizures, highlighting the dire need for more responsive therapies. Non-adherence is a major pressing issue, particularly prevalent among individuals grappling with refractory epilepsy. There is a...
